CD59 and neuromyelitis optica: Little or no abnormalities were seen in control (non-NMO) human IgG-treated CD59+/+ rats, AQP4-IgG-treated CD59+/+ rats, or complement inhibitor / AQP4-IgG-treated CD59−/− rats.